ATE541567T1 - Pharmazeutische zusammensetzung zur prävention und behandlung von metabolischen knochenerkrankungen mit alpha-arylmethoxyacrylat- derivaten - Google Patents

Pharmazeutische zusammensetzung zur prävention und behandlung von metabolischen knochenerkrankungen mit alpha-arylmethoxyacrylat- derivaten

Info

Publication number
ATE541567T1
ATE541567T1 AT05756853T AT05756853T ATE541567T1 AT E541567 T1 ATE541567 T1 AT E541567T1 AT 05756853 T AT05756853 T AT 05756853T AT 05756853 T AT05756853 T AT 05756853T AT E541567 T1 ATE541567 T1 AT E541567T1
Authority
AT
Austria
Prior art keywords
alpha
aryl
prevention
treatment
bone diseases
Prior art date
Application number
AT05756853T
Other languages
English (en)
Inventor
Bum Tae Kim
Yong Ki Min
Yeon Soo Lee
Jung Nyoung Heo
Hyuk Lee
No Kyun Park
Jung-Keun Kim
Se-Won Kim
Seon-Yle Ko
Original Assignee
Korea Res Inst Chem Tech
Oscotec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Res Inst Chem Tech, Oscotec Inc filed Critical Korea Res Inst Chem Tech
Application granted granted Critical
Publication of ATE541567T1 publication Critical patent/ATE541567T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
AT05756853T 2004-06-22 2005-06-22 Pharmazeutische zusammensetzung zur prävention und behandlung von metabolischen knochenerkrankungen mit alpha-arylmethoxyacrylat- derivaten ATE541567T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020040046644A KR100624238B1 (ko) 2004-06-22 2004-06-22 알파-아릴메톡시아크릴레이트 유도체를 함유하는 대사성골 질환의 예방 및 치료용 약학 조성물
PCT/KR2005/001935 WO2005123054A1 (en) 2004-06-22 2005-06-22 Pharmaceutical composition for preventing and treating metabolic bone diseases containing alpha-arylmethoxyacrylate derivatives

Publications (1)

Publication Number Publication Date
ATE541567T1 true ATE541567T1 (de) 2012-02-15

Family

ID=35509437

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05756853T ATE541567T1 (de) 2004-06-22 2005-06-22 Pharmazeutische zusammensetzung zur prävention und behandlung von metabolischen knochenerkrankungen mit alpha-arylmethoxyacrylat- derivaten

Country Status (9)

Country Link
US (2) US7879835B2 (de)
EP (1) EP1784173B1 (de)
JP (1) JP4733698B2 (de)
KR (1) KR100624238B1 (de)
CN (1) CN1968687B (de)
AT (1) ATE541567T1 (de)
DK (1) DK1784173T3 (de)
ES (1) ES2380454T3 (de)
WO (1) WO2005123054A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1310899C (zh) * 2003-11-11 2007-04-18 沈阳化工研究院 具有杀虫、杀菌活性的苯并吡喃酮类化合物及制备与应用
US7767657B2 (en) 2005-02-16 2010-08-03 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
JP5038912B2 (ja) 2005-02-16 2012-10-03 アナコール ファーマシューティカルズ，インコーポレイテッド ホウ素含有小分子
KR100720026B1 (ko) * 2005-06-22 2007-05-21 한국화학연구원 아미노 치환기를 갖는 알파-아릴메톡시아크릴레이트 유도체및 이를 함유하는 대사성 골 질환의 예방 및 치료용 약학조성물
MX335993B (es) * 2005-12-30 2016-01-07 Anacor Pharmaceuticals Inc Moleculas pequeñas que contienen boro.
KR20080111021A (ko) * 2006-03-29 2008-12-22 바스프 에스이 철 대사 장애의 치료를 위한 스트로빌루린의 용도
CN101311170B (zh) * 2007-05-25 2010-09-15 中国中化股份有限公司 取代嘧啶醚类化合物及其应用
WO2009148874A2 (en) * 2008-05-29 2009-12-10 Osteogenex Inc. Gamma-lactam compounds for promoting bone growth
CN102510854A (zh) * 2010-04-21 2012-06-20 奥斯考泰克公司 α-芳基甲氧基丙烯酸酯衍生物、其制备方法和包含所述衍生物的药物组合物
CN105037258A (zh) * 2015-06-17 2015-11-11 中化化工科学技术研究总院 杀菌剂啶氧菌酯原药中一种杂质的制备方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0278595B2 (de) * 1987-02-09 2000-01-12 Zeneca Limited Fungizide
EP0335519A1 (de) * 1988-03-31 1989-10-04 Imperial Chemical Industries Plc Insektizide
US5104872A (en) * 1989-08-22 1992-04-14 Nihon Hohyaku Co., Ltd. N-(substituted benzyloxy) imine derivatives and method of use thereof
DE59109047D1 (de) * 1990-06-27 1998-10-08 Basf Ag O-Benzyl-Oximether und diese Verbindungen enthaltende Pflanzenschutzmittel
NZ242290A (en) * 1991-04-15 1994-12-22 Zeneca Ltd Pyridyl and pyrimidinyl substituted oxime-o-benzyl ether derivatives; preparatory processes, fungicidal compositions and an intermediate
PL315668A1 (en) * 1994-01-27 1996-11-25 Ciba Geigy Ag Method of obtaining derivatives of aryloacetic ester by palladium-catalysed cross-coupling reaction
ITMI20020814A1 (it) * 2002-04-17 2003-10-17 Isagro Ricerca Srl Nuovi analoghi delle strobilurine e loro uso quali acaricidi e insetticidi

Also Published As

Publication number Publication date
US20080280901A1 (en) 2008-11-13
WO2005123054A1 (en) 2005-12-29
KR20050121491A (ko) 2005-12-27
DK1784173T3 (da) 2012-05-07
JP4733698B2 (ja) 2011-07-27
JP2008503567A (ja) 2008-02-07
KR100624238B1 (ko) 2006-09-19
CN1968687A (zh) 2007-05-23
EP1784173B1 (de) 2012-01-18
EP1784173A4 (de) 2009-07-01
CN1968687B (zh) 2013-11-06
US7879835B2 (en) 2011-02-01
ES2380454T3 (es) 2012-05-11
EP1784173A1 (de) 2007-05-16
US8227456B2 (en) 2012-07-24
US20100256367A1 (en) 2010-10-07

Similar Documents

Publication Publication Date Title
EP1851237A4 (de) Pharmazeutische zusammensetzungen zur behandlung oder prävention von knochenerkrankungen
ATE484494T1 (de) Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
EA200800798A1 (ru) Фармацевтические композиции, предназначенные для лечения нарушений внутреннего уха
UA92000C2 (en) 1-benzylindole-2-carboxamide derivatives
ATE539078T1 (de) Isoxazolderivate enthaltende pharmazeutische zusammensetzung zur prävention und behandlung von restenose
ATE456369T1 (de) Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
CY1118179T1 (el) Φαρμακευτικη συνθεση
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
SG178975A1 (en) Indenone derivative and pharmaceutical composition comprising same
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
ATE410424T1 (de) Spirocyclische cyclohexan-derivate
DE602004017326D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
EP4000609A4 (de) Pharmazeutische zusammensetzung zur vorbeugung oder behandlung von knochenerkrankungen
DK1784173T3 (da) Farmaceutisk sammensætning til forebyggelse og behandling af metaboliske knoglesygdomme indeholdende alpha-arylmethoxyacrylatderivater
EA200702282A1 (ru) Комбинация феррохина и производного артемизинина для лечения малярии
DE602005010744D1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
JP2019529569A5 (de)
EA200602002A1 (ru) Применение спинозинов для заживления ран
TW200635595A (en) Medicaments for the treatment of prevention of fibrotic diseases
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
ATE399758T1 (de) Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten
ATE496899T1 (de) Tetrahydro- und dihydrochinazolinone
ATE477820T1 (de) Pharmazeutische zusammensetzungen zur oralen verabreichung bei der behandlung von adipositas- patienten